Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary epithelial apoptosis.
Using a novel transgenic mouse model of spontaneous mammary carcinoma, we show here that the IL-12/pulse IL-2 combination can induce rapid and complete regression of well-established autochthonous tumor in a setting where the host immune system has been conditioned by the full dynamic process of neoplastic progression and tumorigenesis. Further, this regimen inhibits neovascularization of established mammary tumors, and does so in conjunction with potent local induction of genes encoding the IFN-gamma- and TNF-alpha-inducible antiangiogenic chemokines IFN-inducible protein 10 and monokine induced by IFN-gamma. In contrast to untreated juvenile C3(1)TAg mice in which histologically normal mammary epithelium predictably undergoes progressive hyperplasia, atypical changes, and ultimately transition to overt carcinoma, the current studies also demonstrate a unique preventative therapeutic role for IL-12/pulse IL-2. In juvenile mice, early administration of IL-12/pulse IL-2 markedly limits the expected genetically programmed neoplastic transition within the mammary epithelium and does so in conjunction with enhancement of constitutive Fas and pronounced induction of local Fas ligand gene expression, T cell infiltration, and induction of apoptosis within the mammary epithelium. These events occur in the absence of a durable Ag-specific memory response. Thus, this novel model system demonstrates that the potent therapeutic activity of the IL-12/pulse IL-2 combination rapidly engages potent apoptotic and antiangiogenic mechanisms that remain active during the delivery of IL-12/pulse IL-2. The results also demonstrate that these mechanisms are active against established tumor as well as developing preneoplastic lesions.
Wigginton
J M
JM
Pediatric Oncology Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD 20892, USA.
Park
J W
JW
Gruys
M E
ME
Young
H A
HA
Jorcyk
C L
CL
Back
T C
TC
Brunda
M J
MJ
Strieter
R M
RM
Ward
J
J
Green
J E
JE
Wiltrout
R H
RH
D000367:Age Factors; D020533:Angiogenesis Inhibitors / Q000096:biosynthesis; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017209:Apoptosis / Q000235:genetics / Q000276:immunology*; D002471:Cell Transformation, Neoplastic / Q000235:genetics* / Q000276:immunology / Q000473:pathology; D018925:Chemokines / Q000096:biosynthesis; D004847:Epithelial Cells / Q000276:immunology / Q000473:pathology / Q000648:ultrastructure; D053222:Fas Ligand Protein; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000276:immunology; D007274:Injections, Intraperitoneal; D007371:Interferon-gamma / Q000096:biosynthesis / Q000502:physiology; D018664:Interleukin-12 / Q000008:administration & dosage; D007376:Interleukin-2 / Q000008:administration & dosage; D008024:Ligands; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology* / Q000473:pathology; D008325:Mammary Neoplasms, Experimental / Q000098:blood supply / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D008562:Membrane Glycoproteins / Q000096:biosynthesis / Q000235:genetics; D051379:Mice; D008815:Mice, Inbred Strains; D008822:Mice, Transgenic; D009389:Neovascularization, Pathologic / Q000276:immunology / Q000517:prevention & control; D012074:Remission Induction; D013601:T-Lymphocytes / Q000276:immunology* / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis; D015854:Up-Regulation / Q000276:immunology; D019014:fas Receptor / Q000096:biosynthesis / Q000235:genetics*
D020533:Angiogenesis Inhibitors; D018925:Chemokines; D053222:Fas Ligand Protein; C505658:Fasl protein, mouse; D007376:Interleukin-2; D008024:Ligands; D008562:Membrane Glycoproteins; D014409:Tumor Necrosis Factor-alpha; D019014:fas Receptor; D018664:Interleukin-12; D007371:Interferon-gamma